Chemed (CHE) is on investors’ radar after recent trading action, with the stock last closing at US$434.53. That move comes against a mixed return profile over the past year and the past 3 months.
See our latest analysis for Chemed.
The recent 1-month share price return of 12.98% contrasts with a 1-year total shareholder return that declined 24.46%. This suggests that near term momentum has picked up after a weaker stretch for longer term holders.
If this kind of late upswing in sentiment has you wondering what else might be setting up for a recovery, it could be worth checking out 19 top founder-led companies
With Chemed trading at US$434.53, sitting close to its analyst price target yet flagged by some models as at a roughly 37% intrinsic discount, the key question is whether this mixed signal hints at a genuine opportunity or a market that is already pricing in future growth.
Most Popular Narrative: 1.9% Undervalued
Chemed’s widely followed fair value of $443 sits slightly above the last close at $434.53. This frames the recent rebound as more than just a short term swing.
The ramp-up of new Certificate of Need (CON) locations in underserved Florida counties (e.g., Pinellas and Marion) is expected to materially expand VITAS's service footprint, aligning with the continued aging U.S. population and the shift toward home-based care, both key drivers of higher patient volumes and long-term top-line revenue growth.
Want to see what sits behind that growth story? The narrative leans on steadily rising revenue, firmer margins, and a future earnings multiple that is noticeably lower than today. The full set of assumptions is where the valuation really comes into focus.
Result: Fair Value of $443 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, there are still clear pressure points, including Medicare reimbursement caps at VITAS and weaker residential demand at Roto-Rooter, both of which could knock this narrative off course.
Find out about the key risks to this Chemed narrative.
Next Steps
With sentiment clearly mixed around Chemed, it may be useful to act promptly, review the full data set, and consider both sides of the story using 3 key rewards and 1 important warning sign
Looking for more investment ideas?
If Chemed has you thinking more broadly about where to put your next dollar to work, it is worth lining up a few fresh ideas before the market moves.
- Target resilient cash generators and see which companies combine quality, income, and a margin of safety with 51 high quality undervalued stocks
- Prioritise steadier rides by checking out companies with stronger balance sheets and fewer red flags using the 66 resilient stocks with low risk scores
- Spot potential early standouts before they hit everyone’s radar by reviewing the screener containing 21 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com